Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024年11月14日 - 7:05AM
ビジネスワイヤ（英語）
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced that on October 22, 2024, the Compensation
Committee of Guardant’s Board of Directors approved the granting of
restricted stock units (“RSUs”) representing 233,603 shares of its
common stock to 123 new non-executive employees and non-qualified
stock option awards to purchase an aggregate of 50,349 shares of
its common stock to three new non-executive employees with a grant
date of November 8, 2024 under the Guardant Health, Inc. 2023
Employment Inducement Incentive Award Plan (the “Inducement Plan”).
The RSUs and stock options were granted as inducements material to
the employees entering into employment with Guardant in accordance
with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
Guardant, or following a bona fide period of non-employment, as an
inducement material to such individuals’ entering into employment
with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
One-third of the shares underlying each RSU award vest on an
annual basis on the anniversary of the vesting commencement date,
subject to each employee’s continued employment with Guardant as of
each such vesting date. The RSUs are subject to the terms and
conditions of the Inducement Plan and the terms and conditions of a
RSU award agreement covering the grant.
All stock options have an exercise price of $28.16 per share,
which is equal to the closing price of Guardant’s common stock on
The Nasdaq Global Select Market on November 8, 2024. One-third of
the shares underlying each stock option award vest on the one-year
anniversary of the vesting commencement date and continue to vest
monthly thereafter over 24 months, subject to each employee’s
continued employment with Guardant as of each such vesting date.
The stock options are subject to the terms and conditions of the
Inducement Plan and the terms and conditions of a stock option
award agreement covering the grant.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241113633438/en/
Investor Contact: Zarak Khurshid
investors@guardanthealth.com
Media Contact: Melissa Marasco press@guardanthealth.com
+1 650-647-3711
Guardant Health (NASDAQ:GH)
過去 株価チャート
から 10 2024 まで 11 2024
Guardant Health (NASDAQ:GH)
過去 株価チャート
から 11 2023 まで 11 2024
